News
Zacks.com on MSN4h
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine ArexvyGSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...
The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback